Literature DB >> 8125668

Factors responsible for the development of avascular necrosis secondary to the treatment of congenital dislocation of the hip.

J Burgos-Flores1, G Ocete-Guzman, P Gonzalez-Herranz, E Hevia-Sierra, S Amaya-Alarcon.   

Abstract

We present 104 cases of unilateral congenital dislocation of the hip treated with the same regime between 1977 and 1988. The patients had an average age of 12 months (range 4-24). The average age at follow-up was 6 years (range 3-13). The incidence of avascular necrosis was 37%. Avascular necrosis presented most frequently in babies of 7 months at the start of treatment, in Tonnis type IV when an adductor tenotomy was not performed, and after open reductions. The most influential factor was the absence of the femoral head descent at the end of the period of traction. The "effective" prereduction traction and the performance of an adductor tenotomy when necessary were the principle factors in avoiding avascular necrosis.

Entities:  

Mesh:

Year:  1993        PMID: 8125668     DOI: 10.1007/bf00181705

Source DB:  PubMed          Journal:  Int Orthop        ISSN: 0341-2695            Impact factor:   3.075


  19 in total

Review 1.  Reduction of congenital dislocation of the hip.

Authors:  G M Gabuzda; T S Renshaw
Journal:  J Bone Joint Surg Am       Date:  1992-04       Impact factor: 5.284

2.  The treatment of congenital dislocation and subluxation of the hip in the older child.

Authors:  G Morel
Journal:  Acta Orthop Scand       Date:  1975-06

3.  Follow-up study of the early treatment of congenital dislocation of the hip.

Authors:  C H CREGO; J R SCHWARTZMANN
Journal:  J Bone Joint Surg Am       Date:  1948-04       Impact factor: 5.284

4.  Avascular necrosis of the capital femoral epiphysis as a complication of closed reduction of congenital dislocation of the hip. A critical review of twenty years' experience at Gillette Children's Hospital.

Authors:  J R Gage; R B Winter
Journal:  J Bone Joint Surg Am       Date:  1972-03       Impact factor: 5.284

5.  Avascular necrosis of the femoral head as a complication of treatment for congenital dislocation of the hip in young children: a clinical and experimental investigation.

Authors:  R B Salter; J Kostuik; S Dallas
Journal:  Can J Surg       Date:  1969-01       Impact factor: 2.089

6.  Closed reduction by two-phase skin traction and functional splinting in mitigated abduction for treatment of congenital dislocation of the hip.

Authors:  J Krämer; R Schleberger; R Steffen
Journal:  Clin Orthop Relat Res       Date:  1990-09       Impact factor: 4.176

7.  Avascular necrosis following closed reduction of congenital dislocation of the hip. Review of influencing factors and long-term follow-up.

Authors:  D I Brougham; N S Broughton; W G Cole; M B Menelaus
Journal:  J Bone Joint Surg Br       Date:  1990-07

8.  Management strategy for prevention of avascular necrosis during treatment of congenital dislocation of the hip.

Authors:  J R Buchanan; R B Greer; J M Cotler
Journal:  J Bone Joint Surg Am       Date:  1981-01       Impact factor: 5.284

9.  Surgical therapy for congenital dislocation of the hip in patients who are twelve to thirty-six months old.

Authors:  M E Berkeley; J H Dickson; T E Cain; M M Donovan
Journal:  J Bone Joint Surg Am       Date:  1984-03       Impact factor: 5.284

10.  Congenital dislocation of the hip. The relationship of premanipulation traction and age to avascular necrosis of the femoral head.

Authors:  D S Weiner; W A Hoyt; H W O'dell
Journal:  J Bone Joint Surg Am       Date:  1977-04       Impact factor: 5.284

View more
  1 in total

Review 1.  Treatment of decentered developmental dysplasia of the hip under the age of 1 year: an evidence-based clinical practice guideline - Part 2.

Authors:  Pieter Bas de Witte; Christiaan J A van Bergen; Babette L de Geest; Floor Willeboordse; Joost H van Linge; Yvon M den Hartog; Magritha Margret M H P Foreman-van Drongelen; Renske M Pereboom; Simon G F Robben; Bart J Burger; M Adhiambo Witlox; Melinda M E H Witbreuk
Journal:  EFORT Open Rev       Date:  2022-08-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.